Eidos Therapeutics Inc

Eidos Therapeutics — Investor Presentation (September 2020)

30 slides from Eidos Therapeutics's investor presentation, Sep 29, 2020

  1. Slide 1: Eidos corporate overview Q3 2020

    Eidos corporate overview Q3 2020 Art | ATTRwt-CM patient Exhibit 99.1

  2. Slide 2: Eidos forward-looking statements

    Eidos forward-looking statements This presentation contains forward-looking statements about Eidos Therapeutics, Inc. (“we,” “Eidos,” or the “Company”). All statements other than statements of historical facts contained in this presentation are forward-looking statements, including the statements ab

  3. Slide 3: Eidos at a glance

    Eidos at a glance Addressing large and growing unmet need in transthyretin (TTR) amyloidosis (ATTR), a fatal disease with limited treatment options Targeting the disease at its source by stabilizing TTR; validated mechanism designed to mimic naturally occurring rescue mutation Advancing acoramidis (

  4. Slide 4: Company is led by proven team with expertise in genetic and cardiovascular medicine

    Company is led by proven team with expertise in genetic and cardiovascular medicine Neil Kumar (Director) William Lis (Director) Suzanne Hooper (Director) Duke Rohlen (Director) Led by industry veterans with over 30 INDs and more than 10 approved drugs Neil Kumar, PhD, CEO Jonathan Fox, MD, PhD, Pre

  5. Slide 5: Disease background and therapeutic hypothesis

    Disease background and therapeutic hypothesis Len | ATTRm-CM patient

  6. Slide 6: Transthyretin (TTR) amyloidosis (ATTR) is a systemic disease with multiple manifestations

    Transthyretin (TTR) amyloidosis (ATTR) is a systemic disease with multiple manifestations Source: Grogan, M et al. JACC 2016, 68:1014-20; Planté-Bordeneuve, V. and Said, G. Lancet Neurol 2011, 10:1086-97 Systemic disease with high burden Central nervous system Ocular Gastrointestinal Nephropathy Car

  7. Slide 7: Opportunity in ATTR-CM growing as patients identified in broader cardiology populations

    Opportunity in ATTR-CM growing as patients identified in broader cardiology populations Gonzalez-Lopez, E. et al. European Heart Journal 2015. Mohammed, S.F. et al. JACC: Heart Failure 2014. Horvath, S.A. et al. Circulation 2018. Castano, A., et al. Eur Heart J 2017. Sperry, B.W. et al. JACC 2018. J

  8. Slide 8: Acoramidis is designed to treat TTR amyloidosis at its source

    Acoramidis is designed to treat TTR amyloidosis at its source Native TTR circulates in blood as a tetramer Dissociation into monomers initiates pathogenesis Monomers aggregate, causing disease Acoramidis stabilizes TTR tetramers, preventing dissociation and halting disease progression Disease mechan

  9. Slide 9: Higher dose of TTR stabilizer (tafamidis) demonstrated greater clinical benefit in ATTR-ACT + long-term extension

    Higher dose of TTR stabilizer (tafamidis) demonstrated greater clinical benefit in ATTR-ACT + long-term extension Phase 3 ATTR-ACT study tested two doses of tafamidis (20 mg & 80 mg) vs. placebo In an analysis of ATTR-ACT combined with long-term extension (LTE), benefit of tafamidis 80 mg vs. 20 mg

  10. Slide 10: Clinical benefit was correlated with extent of TTR stabilization or knockdown in ATTR-PN clinical studies

    Clinical benefit was correlated with extent of TTR stabilization or knockdown in ATTR-PN clinical studies % peak stabilization/knockdown ~45% ~75% ~75% ~85% * Statistically significant improvement on primary endpoint Note: Direct cross-study comparisons may suggest misleading similarities or differe

  11. Slide 11: Human genetics suggest TTR stability is associated with disease severity

    Human genetics suggest TTR stability is associated with disease severity kdiss = dissociation constant Source: Hammarstrom, P. et al. PNAS 2002, 99:16427-16432 Relative TTR tetramer stability kdiss, WT / kdiss, mutant Disease severity Carriers protected against ATTR Low ATTR penetrance, late onset w

  12. Slide 12: Stabilizing TTR may be protective beyond ATTR

    Stabilizing TTR may be protective beyond ATTR Source: Hornstrup, L.S. et al. Arterioscler Thromb Vasc Biol 2013 33:1441-1447 Prospective studies of 68,602 participants, 32 year mean follow up, in Denmark: Higher circulating TTR concentration Protection against vascular diseases Transthyretin concent

  13. Slide 13: Acoramidis structurally mimics disease-protective T119M mutation

    Acoramidis structurally mimics disease-protective T119M mutation Disease-protective T119M mutation Acoramidis-bound TTR Strong inter-monomer H-bonds observed via X-ray crystallography Unique binding mode vs other stabilizers

  14. Slide 14: Phase 2 results

    Phil | ATTRwt-CM patient Phase 2 results

  15. Slide 15: Phase 2 ATTR-CM trial provided randomized 28-day and 15-month open label data

    Phase 2 ATTR-CM trial provided randomized 28-day and 15-month open label data SCHEMATIC OF ACORAMIDIS PHASE 2 STUDIES4 OUTCOMES Random-ized portion 28 days Open label extension Ongoing 17 Placebo 49 Patients underwent randomization 16 Acoramidis 400mg 16 Acoramidis 800mg 2 Declined1 47 (96%) Continu

  16. Slide 16: Baseline characteristics highlight advanced disease stage of trial participants

    Baseline characteristics highlight advanced disease stage of trial participants 1NT-proBNP = N-Terminal pro B-type Natriuretic Peptide, normal range = 0 – 449 pg/mL 2TnI = troponin I, normal range = 0 – 0.02 ng/mL 3TTR = transthyretin (prealbumin), normal range = 20 – 40 mg/dL ATTRm-CM variants (n)

  17. Slide 17: Fewer adverse events occurred in acoramidis-treated participants than placebo-treated participants during randomized portion

    Fewer adverse events occurred in acoramidis-treated participants than placebo-treated participants during randomized portion AF = Atrial Fibrillation; CHF = Congestive Heart Failure 1 Subject experienced 2 SAEs of AF and CHF Atrial fibrillation Muscle spasms Constipation Diarrhea Most frequent AEs (

  18. Slide 18: Acoramidis treatment increased serum TTR concentrations in a dose-dependent manner

    Serum TTR concentration Δ from baseline to day 28 (%) Acoramidis treatment increased serum TTR concentrations in a dose-dependent manner ATTRwt-CM ATTRm-CM 1 Normal reference range for serum TTR 20-40 mg/dL (3.6-7.3 µM) Note: Serum TTR concentrations not available at baseline for one 400 mg subject

  19. Slide 19: No safety signals of clinical concern identified during open label extension

    No safety signals of clinical concern identified during open label extension 1 Includes 2 subjects who had SAEs with an outcome of death (1 disease progression; 1 cervix carcinoma); 1 subject died due to heart failure 86 days after the last dose of study drug Data reported as of 8/31/2019 in conjunc

  20. Slide 20: Near-complete stabilization of TTR maintained throughout Phase 2 study

    Near-complete stabilization of TTR maintained throughout Phase 2 study 1 Reported occupancy >100% caused by background protein fluorescence Stabilization of TTR by Western blot assay Occupancy of TTR by Fluorescent Probe Exclusion assay TTR stabilization at steady-state trough level %, mean ± SEM AG

  21. Slide 21: Serum TTR levels increased upon acoramidis treatment and were maintained throughout study duration

    Serum TTR levels increased upon acoramidis treatment and were maintained throughout study duration Serum TTR concentration mg/dL, mean ± SEM AG10-202 (OLE) Visit Day AG10-201 (R) AG10-202 (OLE) Rollover OLE baseline OLE baseline +39% +56% Acoramidis WT1 Acoramidis Variant1 Placebo WT Placebo Variant

  22. Slide 22: Below normal serum TTR concentrations were associated with poorer survival in ATTR-CM patients

    Below normal serum TTR concentrations were associated with poorer survival in ATTR-CM patients Source: Hanson, J.L.S. et al. Circ Heart Fail 2018 11:e004000; Nativi-Nicolau, J. Circ Heart Fail. 2018; 11:e004802. DOI: 10.1161/CIRCHEARTFAILURE.118.004802 Survival probability stratified by baseline TTR

  23. Slide 23: NT-proBNP and TnI were unchanged in acoramidis-treated participants throughout OLE

    NT-proBNP and TnI were unchanged in acoramidis-treated participants throughout OLE NT-proBNP AG10-202 (OLE) Visit Day 1 14 45 90 180 270 pg/mL; 95% confidence interval, quartiles, median TnI ng/mL; 95% confidence interval, quartiles, median AG10-202 (OLE) Visit Day 1 14 45 90 180 270

  24. Slide 24: Echocardiography parameters were unchanged in acoramidis-treated participants throughout OLE

    Echocardiography parameters were unchanged in acoramidis-treated participants throughout OLE Left ventricular mass Left ventricular stroke volume index AG10-202 (OLE) Visit Day AG10-202 (OLE) Visit Day 1 90 180 270 1 90 180 270 g; 95% confidence interval, quartiles, median mL/m2; 95% confidence inte

  25. Slide 25: Participants in the acoramidis Phase 2 study had similar baseline characteristics as those in the ATTR-ACT study

    Participants in the acoramidis Phase 2 study had similar baseline characteristics as those in the ATTR-ACT study 1 Maurer, M.S. et al. N Engl J Med. 2018;379:1007–16 2 Judge, D.P. et al. JACC Vol. 74, No. 3, 2019:285 – 95 Baseline characteristics from ATTR-ACT study and acoramidis Phase 2 study ATTR

  26. Slide 26: Deaths and CV hospitalizations reported in acoramidis Phase 2 OLE were lower than in placebo-treated ATTR-ACT participants

    Deaths and CV hospitalizations reported in acoramidis Phase 2 OLE were lower than in placebo-treated ATTR-ACT participants All-cause mortality at 15 months Participants died or receiving transplant (%) Cardiovascular hospitalizations at 15 months Participants with ≥1 CV hospitalization (%) 1 Based o

  27. Slide 27: Phase 3 trial and company catalysts

    Phase 3 trial and company catalysts Ivan | ATTRwt-CM patient

  28. Slide 28: Two-part trial design includes 12-month and 30-month registrable endpoints

    Two-part trial design includes 12-month and 30-month registrable endpoints ATTRibute-CM study schematic Subjects with diagnosed ATTR-CM (WT or mutant) NYHA Class I-III Positive biopsy or 99mTc scan Negative serum/ urine light chain if dx by 99mTc scan Key inclusion criteria 800 mg acoramidis twice d

  29. Slide 29: ATTRibute-CM Phase 3 study is expected to provide top-line data in late 2021 or early 2022

    ATTRibute-CM Phase 3 study is expected to provide top-line data in late 2021 or early 2022 CC We believe the company is well capitalized for the ATTRibute-CM trial with $175M in cash (6/30/2020) ANTICIPATED Update ATTRibute-PN Phase 3 initiation ATTRibute-CM Part A top-line data Expected timing ATTR

  30. Slide 30: Thank you

    Thank you Art | ATTRwt-CM patient

Eidos Therapeutics — Investor Presentation (September 2020) on 6ix